Related Blog Posts from the Wikinvest Wire

Pfizer (PFE)   Subscribe to Pfizer (PFE) content from the Wikinvest Wire
 » Back to Pfizer (NYSE:PFE) Stock Page

  

12/16/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to View and Listen to Webcast of ... (Jutia Group)

[Business Wire] - Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 27, 2015. The Read more on this. Pfizer Inc. (PFE), valued at $196.36B, opened at $30.76.   Today, [...]

12/15/14Company Update (NYSE:PFE): Pfizer Declares First-Quarter 2015 Dividend (Jutia Group)

[Business Wire] - The board of directors of Pfizer Inc. today declared a 28-cent first-quarter 2015 dividend on the company’s common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015. Read more on this. Pfizer Inc. (PFE), currently valued at $195.10B, started trading this [...]

12/3/14Company Update: Pfizer Inc (NYSE:PFE) – Phase 3 Results Published in The New England Journal of... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today the publication of results from the PROFILE 1014 study in the December 4 issue of The New England Journal of Medicine. PROFILE 1014 is a Phase 3 study of anaplastic lymphoma kinase inhibitor XALKORI® in previously untreated patients with ALK-positive advanced non-small cell lung cancer . Read [...]

12/1/14Stock Update (NYSE:PFE): Pfizer Completes Acquisition of Baxter’s Marketed Vaccines (Jutia Group)

[Business Wire] - Pfizer Inc. today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. Read more on this. Pfizer Inc. (PFE), with a current value of $197.90B, opened at $30.88.   A quick [...]

11/26/14Market Update: Pfizer Inc (NYSE:PFE) – BUZZ-AstraZeneca: Pfizer may turn M&A sights on Mylan -J... (Jutia Group)

[Reuters - UK Focus] - ** Pfizer can resume its pursuit of AstraZeneca from today as 6-month cooling-off period ends but chances of a fresh bid seen as slim, especially after the U.S. drugmaker's big oncology deal with Merck ... Read more on this. Pfizer Inc. (PFE), with a current value of $193.05B, [...]

11/18/14Stock Update (NYSE:PFE): AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer (Jutia Group)

[Reuters - UK Focus] - AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer ... Read more on this. Pfizer Inc. (PFE), with a current market cap of $191.22B, opened this morning [...]

11/13/14Company Update: Pfizer Inc (NYSE:PFE) – Novel Agreement Expands Access to Pfizer’s Contracept... (Jutia Group)

[Business Wire] - NEW YORK--(BUSINESSWIRE)-- Pfizer Inc., the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation (CIFF) today announced an agreement that will expand access to Pfizer’s injectable ... Read more on this. Pfizer Inc. (PFE), with a current value of $191.94B, started the session at $30.52.   [...]

10/29/14Market Update (NYSE:PFE): Pfizer’s PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Se... (Jutia Group)

[Business Wire] - Pfizer Inc. today announced the publication of a clinical study in the Journal of Clinical Psychiatry showing comparable sexual function in adult patients diagnosed with major depressive disorder treated daily with PRISTIQ Extended Release Tablets 50mg and 100mg doses versus placebo. Read more on this. Pfizer Inc. (PFE), valued at [...]

10/27/14Market Update: Pfizer Inc (NYSE:PFE) – DURECT Provides Update on REMOXY® and POSIDUR™ Programs (Jutia Group)

[PR Newswire] - CUPERTINO, Calif., Oct. 27, 2014 /PRNewswire/ -- DURECT Corporation (DRRX) reported today that Pfizer Inc. (PFE) announced today that it has notified Pain Therapeutics, Inc. (PTIE) that Pfizer has decided to discontinue its agreement to develop and commercialize REMOXY® (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone. Pfizer [...]

10/23/14Company Update (NYSE:PFE): Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend (Jutia Group)

[Business Wire] - The board of directors of Pfizer Inc. today declared a 26-cent fourth-quarter 2014 dividend on the company’s common stock, payable December 2, 2014, to shareholders of record at the close of business on November 7, 2014. Read more on this. Pfizer Inc. (PFE), valued at $181.35B, began trading this morning [...]

10/16/14Stock Update (NYSE:PFE): FDA panel votes to keep severe warning on Pfizer anti-smoking drug (Jutia Group)

[Reuters] - Pfizer Inc failed to convince the U.S. Food and Drug Administration to remove a black box warning on its controversial quit-smoking drug Chantix, with an advisory panel to the agency voting against the removal on Thursday. A majority of the panel voted to keep the health regulator's most severe warning label on [...]

10/14/14Market Update: Pfizer Inc (NYSE:PFE) – FDA staff wants Pfizer to keep black box warning on anti... (Jutia Group)

[Reuters] - Food and Drug Administration staff recommended that Pfizer Inc keep a severe warning on its controversial quit-smoking drug Chantix. Approved in 2006, Chantix has been one of Pfizer's most controversial drugs, after severe side effects including suicidal thoughts, erratic behavior and drowsiness came to light in 2007. The FDA placed a black [...]

10/13/14Stock Update (NYSE:PFE): Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With... (Jutia Group)

[Business Wire] - Pfizer Inc. today announced the New Drug Application for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration . Read more on this. Pfizer Inc. (PFE), valued at $184.08B, opened this morning at $29.14.   During the trading [...]

9/25/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Completes Acquisition Of InnoPharma (Jutia Group)

[Business Wire] - Pfizer Inc. today announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States Read more on this. Pfizer Inc. (PFE), valued at $190.10B, began trading this morning at $30.31.   Today, shares have traded between $29.97 and $30.37 [...]

9/23/14Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to View and Listen to Webcast of Oc... (Jutia Group)

[Business Wire] - Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 28, 2014. The Read more on this. Pfizer Inc. (PFE), valued at $190.23B, started trading this morning at $29.83.   [...]

9/22/14Stock Update: Pfizer Inc (NYSE:PFE) – Bristol-Myers Squibb and Pfizer Announce Charitable Donat... (Jutia Group)

[Business Wire] - Bristol-Myers Squibb Company and Pfizer Inc. today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease. Read more on this. Pfizer Inc. (PFE), with a current market cap of $190.10B, opened at $30.26. [...]

9/3/14Stock Update (NYSE:PFE): Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healt... (Jutia Group)

[Business Wire] - Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, Group President, Global Innovative Pharma Business, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2014 at 12:55 p.m. Read more on this. Pfizer Inc. (PFE), with a current [...]

8/28/14Company Update (NYSE:PFE): Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric... (Jutia Group)

[Business Wire] - Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the U.S. Food and Drug Administration approved ELELYSO™ for injection for pediatric patients. Read more on this. Pfizer Inc. (PFE), valued at $186.29B, opened this morning at $29.43.   Shares have traded today between $29.36 and $29.67 per [...]

8/18/14Stock Update (NYSE:PFE): Pfizer Announces Submission of Palbociclib New Drug Application to the FDA (Jutia Group)

[Business Wire] - Pfizer Inc. today announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive , human epidermal growth factor receptor [...]

8/14/14Market Update (NYSE:PFE): Pfizer Announces FDA Acceptance Of And Priority Review Designation For ... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086 , the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. Read more on this. [...]

8/13/14 (Jutia Group)

[at noodls] - NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar ... Read more on this. Pfizer Inc. (PFE), with a current value of $178.88B, opened at $28.25.   During the trading [...]

8/12/14Stock Update (NYSE:PFE): Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful ... (Jutia Group)

[at noodls] - NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica® (pregabalin) in patients with postherpetic neuralgia ... Read more on this. Pfizer Inc. (PFE), valued at $178.05B, began trading this morning at $28.26.   Looking at today's trading action, [...]

8/7/14Company Update (NYSE:PFE): Pfizer confronts surge of lawsuits over Lipitor (Jutia Group)

[Reuters] - Pharmaceutical giant Pfizer is facing a mounting wave of lawsuits by women who allege that the company knew about possible serious side effects of its blockbuster anti-cholesterol drug Lipitor but never properly warned the public. In the past five months, a Reuters review of federal court filings shows, lawsuits by U.S. women [...]

8/7/14Stock Update (NYSE:PFE): Illinois gets $1.3 million in Pfizer settlement (Jutia Group)

[AP] - Illinois will receive $1.3 million as part of a $35 million settlement with a Pfizer Inc. over the marketing of an organ-transplant drug. Illinois and 41 other states are involved in the settlement with ... Read more on this. Pfizer Inc. (PFE), valued at $180.33B, started the session at $28.44. [...]

8/6/14Company Update (NYSE:PFE): Pfizer to pay $35 mln to U.S. states to settle Rapamune claims (Jutia Group)

[Reuters] - Pfizer Inc agreed to pay $35 million to 41 U.S. states and Washington, D.C. to settle claims that its Wyeth unit illegally marketed the drug Rapamune, and encouraged doctors and hospitals to prescribe it for off-label uses. The settlement was announced on Wednesday, just over one year after Pfizer agreed in July [...]

8/4/14Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Enters Into Agreement To Acquire Baxter’s Portf... (Jutia Group)

[at noodls] - Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.'s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will ... Read more on this. Pfizer Inc. (PFE), with a current value of $182.75B, started trading this morning at [...]

7/30/14Market Update (NYSE:PFE): Pfizer Enters Into Agreement to Acquire Baxter’s Portfolio of Markete... (Jutia Group)

[at noodls] - NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.'s portfolio of marketed vaccines for $635 million. As part of ... Read more on this. Pfizer Inc. (PFE), valued at $185.56B, started the session at $29.51.   Shares [...]

7/29/14Pfizer Inc (NYSE:PFE) | Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ... (Jutia Group)

[at noodls] - Pfizer Inc. (NYSE:PFE) today announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX ® Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment ... Read more on this. Pfizer Inc. (PFE), with a current market cap of $191.60B, opened at $30.33.   [...]

7/25/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Ltd’s Profit from operations before other inco... (Jutia Group)

[at noodls] - NEWS RELEASE Pfizer Ltd's Profit from operations before other income, finance cost and tax for the Quarter increased by 40% Pfizer Ltd announced the results for the first quarter ended June 30, 2014. The ... Read more on this. Pfizer Inc. (PFE), currently valued at $192.80B, started the session at [...]

7/16/14Stock Update (NYSE:PFE): Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG... (Jutia Group)

[at noodls] - Once-Weekly Prophylaxis Treatment with BeneFIX® Significantly Reduced Annualized Bleeding Rate Compared to On-Demand Treatment "Pfizer remains committed to the research and development of new and ... Read more on this. Pfizer Inc. (PFE), with a current market cap of $193.98B, began trading this morning at $30.22.   [...]

6/18/14Pfizer Inc (NYSE:PFE) – French biotech Cellectis surges as Pfizer signs cancer drug deal (Jutia Group)

[Reuters] - * Pfizer secures access to early cancer-hunting CAR-T drugs * Cellectis gets $80 mln upfront, shares soar 50 percent (Adds details on rival Novartis research, more on technology, Cellectis valuation) June 18 (Reuters) - U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca , said on [...]

6/17/14Market Update: Pfizer Inc (NYSE:PFE) – Pfizer Announces Submission of Biologics License Applica... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for bivalent recombinant LP2086 (r Read more on this. Pfizer Inc. (PFE), valued at $188.87B, opened at $29.50.   Looking at today's market, PFE one day range is [...]

6/13/14Pfizer Inc (NYSE:PFE) | Drug-linked payouts: complex fix for Pfizer’s next Astra bid? (Jutia Group)

[Reuters] - The world's biggest would-be drugs merger hit a wall last month but speculation about smart ways that Pfizer could yet seal a deal with AstraZeneca remains intense. Even as talks fell apart last month, some in Pfizer's camp remained optimistic the transaction could be revived - and certain AstraZeneca advisers have not [...]

5/27/14 (Jutia Group)

[Business Wire] - Pfizer Inc. today announced the introduction in the U.S. of over-the-counter Nexium® 24HR, making The Purple Pill® available for the treatment of frequent heartburn in adults . Read more on this. Pfizer Inc. (PFE), with a current value of $189.93B, finished yesterday at $29.49.   Looking at [...]

5/26/14Market Update: Pfizer Inc (NYSE:PFE) – Pfizer walks away from $118 bln AstraZeneca takeover fight (Jutia Group)

[Reuters - UK Focus] - * Pfizer (NYSE: PFE - news) can return in 6 months, or 3 months if invited back (Adds AstraZeneca reaction) LONDON/NEW YORK (Frankfurt: HX6.F - news) , May 26 (Reuters) - Pfizer abandoned its attempt to buy AstraZeneca (NYSE: AZN - news) for nearly 70 billion pounds ($118 billion) [...]

5/23/14Company Update (NYSE:PFE): Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today detailed results from the Oral treatment Psoriasis Trial Retreatment study , a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. Read more on this. Pfizer Inc. (PFE), valued at $188.75B, began trading this morning at $29.60.   [...]

5/22/14Pfizer Inc (NYSE:PFE) – BlackRock wants new Astra-Pfizer talks at later date-sources (Jutia Group)

[Reuters - UK Focus] - BlackRock Inc, AstraZeneca Plc's largest shareholder, wants the drugmaker to resume talks with Pfizer Inc about a potential sale eventually, but backs its decision this week to reject Pfizer's current ... Read more on this. Pfizer Inc. (PFE), with a current value of $189.19B, began trading this morning [...]

5/20/14Company Update: Pfizer Inc (NYSE:PFE) – Schroders, Fidelity reveal investor split as Astra reje... (Jutia Group)

[Reuters] - Schroders said on Tuesday it was disappointed with "the quick rejection by the AstraZeneca board" of an improved 55 pounds-a-share offer and the decision by Pfizer to "draw a premature end to these negotiations by calling their latest proposal final". "Given the increase in the offer we would encourage the AstraZeneca management [...]

5/16/14Company Update (NYSE:PFE): Pfizer To Submit Palbociclib New Drug Application With FDA Based On Fi... (Jutia Group)

[Business Wire] - Pfizer Inc. today announced that it will submit a New Drug Application with the United States Food and Drug Administration for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. Read [...]

5/15/14Stock Update (NYSE:PFE): Pfizer move on Astra threatens UK science, lawmakers say (Jutia Group)

[Reuters] - Pfizer's (PFE) potential takeover of AstraZeneca (AZN.L) poses a threat to British science unless the U.S. drugmaker can give more concrete, enforceable guarantees on jobs and investment, politicians scrutinizing the deal said on Thursday. London-based AstraZeneca has rejected a $106 billion offer from Pfizer and expressed concern that Pfizer would shut down [...]

5/14/14Company Update: Pfizer Inc (NYSE:PFE) – UK lawmaker stirs political row with Pfizer "rapist" co... (Jutia Group)

[Reuters - UK Focus] - A lawmaker from Britain's opposition Labour party stirred a political row on Wednesday after describing U.S. drugmakers Pfizer as "rapists" in comments criticising the government for its handling ... Read more on this. Pfizer Inc. (PFE), currently valued at $186.32B, opened this morning at $29.14.   [...]

5/13/14Pfizer Inc (NYSE:PFE) – UK minister says intervention on AstraZeneca, Pfizer "tricky" (Jutia Group)

[Reuters - UK Focus] - Intervening in Pfizer's proposed acquisition of AstraZeneca using public interest rules is "quite tricky" and could be a lengthy process, British business minister Vince Cable said on Tuesday. ... Read more on this. Pfizer Inc. (PFE), currently valued at $186.70B, started the session at $29.14.   [...]

5/12/14Market Update (NYSE:PFE): Pfizer tightens levels by 10bp-20bp at guidance (Jutia Group)

[Reuters - UK Focus] - NEW YORK (Frankfurt: HX6.F - news) , May 12 (IFR) - Pfizer Inc (NYSE: PFE - news) tightened pricing levels at the guidance stage Monday on its latest multi-part dollar bond by about 10bp to 20bp across the curve. The company, which is currently looking to acquire AstraZeneca (NYSE: [...]

5/9/14Pfizer Inc (NYSE:PFE) – Pfizer Announces Positive Phase 2 Study Results for Investigational Men... (Jutia Group)

[Business Wire] - Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. Read more on this. Pfizer Inc. (PFE), with a current [...]

5/8/14Company Update: Pfizer Inc (NYSE:PFE) – Fitch Solutions: CDS Sentiment Souring for Pfizer, Impr... (Jutia Group)

[Reuters] - Takeover speculation involving AstraZeneca Plc and Pfizer is leading to two very different sentiments with respect to credit default swap (CDS) spread movement, according to Fitch Solutions in its latest CDS case study snapshot. While five-year CDS on AstraZeneca have tightened 21% in the past month, Pfizer's CDS have widened 28%. 'Credit [...]

5/7/14Market Update: Pfizer Inc (NYSE:PFE) – AstraZeneca in partnering talks for Alzheimer’s drug (Jutia Group)

[Reuters - UK Focus] - * AstraZeneca (NYSE: AZN - news) ready to start Phase III tests on BACE drug (Adds quote, details on competitors, background) LONDON, May 7 (Reuters) - AstraZeneca, fighting a $106 billion bid approach from Pfizer (NYSE: PFE - news) , is talking to other companies as it seeks a [...]

5/6/14Company Update (NYSE:PFE): Second UK lawmaker panel to call Pfizer, AstraZeneca over bid (Jutia Group)

[Reuters - UK Focus] - Senior management from U.S. drugmaker Pfizer (NYSE: PFE - news) and British pharmaceutical firm AstraZeneca (NYSE: AZN - news) will be called before a British parliamentary committee to answer questions on a potential takeover deal, the committee chairman said on Tuesday. AstraZeneca on Friday rejected a 63 billion-pound ($106.26 [...]

5/5/14Company Update: Pfizer Inc (NYSE:PFE) – Pfizer’s (PFE) CEO Ian Read on Q1 2014 Results – Ea... (Jutia Group)

[Seeking Alpha] - Good day, everyone and welcome to Pfizer's First Quarter 2014 Earnings Conference Call. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Good morning and thank you for joining us today to review Pfizer's first quarter 2014 performance. Read [...]

5/2/14Market Update: Pfizer Inc (NYSE:PFE) – AstraZeneca rejects Pfizer’s raised bid of $106 bln (Jutia Group)

[Reuters - UK Focus] - U.S. drugmaker Pfizer Inc increased its offer for AstraZeneca Plc to 63 billion pounds on Friday, but the British company promptly rejected the proposal, which would create the world's biggest pharmaceuticals ... Read more on this. Pfizer Inc. (PFE), valued at $196.08B, opened at $31.06.   [...]

5/1/14Market Update (NYSE:PFE): Pfizer prepares sweeter bid for AstraZeneca – report (Jutia Group)

[Reuters - UK Focus] - Pfizer Inc may sweeten its offer for Britain's AstraZeneca Plc to more than 63 billion pounds, or $106 billion, and raise the cash portion of the deal, to kickstart negotiations, Bloomberg reported on ... Read more on this. Pfizer Inc. (PFE), currently valued at $198.70B, opened at $31.09. [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki